SpecificationsOrganism/cell line/tissueHuman primary uterine smooth muscle cellsSexFemaleSequencer or array typeAffymetrix GeneChip® Scanner 3000Data formatRawExperimental factorsNormal term not in labour samplesExperimental featuresPrimary cultures of human myometrial cells were grown from myometrial biopsies obtained at the time of elective caesarean section. Cells were exposed to different stimuli, IL-1β (5 ng/mL) and P4 (10 μM), either alone or in combination for 6 h, and then total RNA were extracted from each culture. Three comparisons were carried out including: 1. V vs. P4; 2. V vs. IL-1β; 3. IL-1β vs. IL-1β + P4.ConsentAll specimens were obtained after fully informed, written patient consent. The Riverside Ethics committee approved the study.Sample source locationLondon, UK

1. Direct link to deposited data {#s0005}
================================

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68171> [@bb0005].

2. Experimental design, materials and methods {#s0010}
=============================================

Primary human myometrial cells were isolated using a mixture of collagenases {1 mg/mL of collagenase 1 A and 1 mg/ml of collagenase XI (Sigma)} and cultured in DMEM medium containing phenol red 7.5% foetal calf serum, [l]{.smallcaps}-glutamine and 100 mU/mL penicillin and 100 μg/mL streptomycin in an atmosphere of 5% CO2: 95% air at 37 °C [@bb0010]. Cells were exposed to IL-1β, P4 either alone or in combination; ethanol was used as the vehicle control for 6 h. Total RNA was extracted and purified from myometrial cells grown in 6-well culture plates using RNAeasy mini kit (Qiagen). cDNA generated from 2 μg of total RNA using the GeneChip® Expression 3′-Amplification One-Cycle cDNA Synthesis Kit, in conjunction with the GeneChip® Eukaryotic PolyA RNA Control Kit (Affymetrix, Inc.). The cDNA was cleaned up using the GeneChip® Sample Cleanup Module and subsequently processed to generate biotin-labelled cRNA using the GeneChip® Expression 3′-amplification IVT Labelling Kit (Affymetrix, Inc.). 25 μg of labelled cRNA was fragmented using 5 × fragmentation buffer and Rnase-free water at 94 °C for 35 min. 15 μg of the fragmented, biotin-labelled cRNA was made up in a hybridization cocktail and hybridised to the HgU133 Plus 2.0 array at 45 °C for 16 h. Following hybridization the arrays were washed and stained using the Affymetrix Fluidics Station 450. GeneChips were scanned using the Affymetrix GeneChip® Scanner 3000. All steps of the process were quality controlled by measuring yield (μg), concentration (μg/L) and 260:280 ratios *via* spectrophotometry using the Nanodrop ND-1000 and sample integrity using the Agilent 2100 bioanalyser (Agilent Technologies, Inc.). After general array quality control and data export, the data were normalised using Robust Multichip Average and imported into Partek Genomic Suite. Array data were then identified for any potential outliers and overall grouping/separation using Principal Component Analysis. The gene lists were generated by a sequential filtering approach based on the fold-change (normalisation to the control group) and the confidence (fold-change p value). The less-stringent gene list resulted from the fold-change greater than 1.5 by comparing the treatment group to the control group. The stringent gene list was obtained by further filtering with fold-change p \< 0.05.
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